Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 13Carcinoma, Renal Cell 6Tuberous Sclerosis 5Neoplasm Metastasis 5Hodgkin Disease 5Glioblastoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Waldenstrom Macroglobulinemia 4Stomach Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Mantle-Cell 4Head and Neck Neoplasms 4Gliosarcoma 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Recurrence 3Prostatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Kidney Neoplasms 3

Interventions

Injections 7pembrolizumab 5Paclitaxel 5Bevacizumab 5Leucovorin 4Fluorouracil 4Carboplatin 4trifluridine tipiracil drug combination 3Pemetrexed 3Oxaliplatin 3Irinotecan 3Docetaxel 3Capecitabine 3toripalimab 2tislelizumab 2fludarabine 2Nivolumab 2Gemcitabine 2Fulvestrant 2Cisplatin 2BMS-753493 2130-nm albumin-bound paclitaxel 2urelumab 1ulixertinib 1palbociclib 1mogamulizumab 1lenvatinib 1fluzoparib 1duvelisib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumors × Everolimus × Clear all
NCT01226056 2010-10-21

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Southern Europe New Drug Organization

Phase 1/2 Suspended
45 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡